PTC Therapeutics price target lowered to $72 from $74 at JPMorgan

JPMorgan analyst Eric Joseph lowered the firm’s price target on PTC Therapeutics (PTCT) to $72 from $74 and keeps an Overweight rating on the shares following the Q4 report. Timelines for the company’s key U.S. regulatory filings for sepiapterin and vatiquinone remain on track with FDA action dates of July 29 and August 19, respectively, the analyst tells investors in a research note.